Consultant Clinician Scientist KSHI, Pediatric Neurophysiologist Johns Hopkins Aramco Healthcare, Adjust assistant professor Johns Hopkins School of medicine
Here, we characterize the disease's first viable transgenic mouse model and also analyze the molecular impact of the VMAT2 mutations in silico to understand the pathophysiology better and potentially improve treatment approaches.
Consultant Clinician Scientist KSHI, Pediatric Neurophysiologist Johns Hopkins Aramco Healthcare, Adjust assistant professor Johns Hopkins School of medicine